NSTM — Novelstem International Income Statement
0.000.00%
- $3.37m
- $7.28m
- $0.01m
Annual income statement for Novelstem International, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2013 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PRESS | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
Standards: | — | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.425 | 0 | 0 | 0.012 | 0.012 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 5.31 | 0.23 | 0.496 | 0.434 | 3.54 |
Operating Profit | -4.89 | -0.23 | -0.496 | -0.422 | -3.53 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 6.45 | -0.214 | -0.502 | -0.433 | -3.88 |
Provision for Income Taxes | |||||
Net Income After Taxes | 6.25 | -0.214 | -0.502 | -0.433 | -3.88 |
Equity in Affiliates | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 6.25 | -0.545 | -1.35 | -0.766 | -4.19 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 6.25 | -0.545 | -1.35 | -0.766 | -4.19 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.276 | -0.013 | -0.03 | -0.016 | -0.089 |
Dividends per Share |